Biotie raises EUR 7.2 million - directed issue of new shares in
Biotie Therapies Corp. more than two
(Thomson Reuters ONE) - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 7 DECEMBER 2009 at9.30 a.m.Biotie raises EUR 7.2 million - directed issue of new shares inBiotie Therapies Corp. more than two times oversubscribedNot for release, publication or distribution, directly or indirectly,in whole or in part, in or into the United States, Australia, Canada,Japan or South Africa.With reference to the share issue announced on 4 December 2009 (the"Offering"), Biotie Therapies Corp. ("Biotie") has decided todiscontinue the reception of subscription undertakings due to theOffering having been oversubscribed more than two times byinternational and Finnish institutional investors.All 14,432,000 shares offered were subscribed at a subscription priceof EUR 0.50 per share. All offered new shares have been allocated toa major UK institutional fund management group on the basis ofrecommendation by Nomura Code Securities Limited, who acted as theLead Manager in the Offering. Moreover, Biotie was informed by theLead Manager that simultaneously with the directed Offering, theywill place certain Biotie shares previously held by certain Europeanventure capital investors to new institutional investors to satisfythe excess demand in the oversubscribed offering.The subscription price for all new shares totalled at EUR 7,216,000and as a result, the share capital of Biotie will be increased bysuch amount. After the registration of the new shares with theFinnish Trade Register, the share capital in Biotie will be EUR51,506,678.10, and the total number of shares will be 158,752,560 andnumber of votes 158,289,305.Timo Veromaa, President and CEO of Biotie, commented: "We are verypleased with the increasing investor interest in the company as weexpect next year to be very exciting for Biotie. All our clinicalprograms are expected to reach decisive points in their developmentwithin the next 18 months and we are happy to see this strong supportfrom the investment community. With the proceeds from this offeringwe have further strengthened our cash position and will be financedwell into 2011".The new shares subscribed will be issued as book-entries in theFinnish book-entry system maintained by Euroclear Finland Ltd andwill be entered on the subscriber's book-entry accounts as interimshares corresponding to the new shares against the payment of thesubscription price on December 11,2009. Trading with the interimshares (ISIN: FI4000007570 and trading symbol: BTH1VN0109) isexpected to commence on 8 December 2009 as a separate class ofsecurities. The interim shares will be combined with Biotie's currentclass of shares after the registration of the new shares with theFinnish Trade Register, on or about 14 December 2009. The new sharesentitle to the exercise of the rights belonging to a shareholder oncethe new shares have been registered with the Finnish Trade Register.In Turku, 7 December 2009Biotie Therapies Corp.Timo VeromaaPresident and CEOFor further information, please contact:Virve Nurmi, Biotie Therapies Corp.tel. +358 2 274 8901, e-mail: virve.nurmi(at)biotie.comwww.biotie.comDISTRIBUTION:NASDAQ OMX Helsinki LtdMain MediaDISCLAIMER:The information herein may not be distributed or sent into the UnitedStates, Australia, Canada, Japan or South Africa. The informationcontained herein shall not constitute an offer to sell or thesolicitation of an offer to buy, nor shall there be any sale of thesecurities referred to herein in any jurisdiction in which suchoffer, solicitation or sale would be unlawful prior to registration,exemption from registration or qualification under the securitieslaws of any such jurisdiction.The information contained herein does not constitute an offer ofsecurities for sale in the United States. The securities referencedin this release may not be offered or sold in the United Statesabsent registration or an exemption from registration as provided inthe United States Securities Act of 1933, as amended, and the rulesand regulations thereunder. Biotie Therapies Corporation does notintend to register any portion of the placement in the United Statesor to conduct a public offering of any securities in the UnitedStates.This communication does not constitute an offer of securities to thepublic in the United Kingdom. This communication is directed only at(i) persons who are outside the United Kingdom, (ii) persons who haveprofessional experience in matters relating to investments fallingwithin Article 19(5) of the Financial Services and Markets Act 2000(Financial Promotion) Order 2005 (the "FP Order") and (iii) high networth entities falling within Article 49(2) of the FP Order, andother persons to whom it may lawfully be communicated, (all suchpersons together being referred to as "relevant persons"). Anyinvestment activity to which this communication relates will only beavailable to, and will only be engaged with, relevant persons. Anyperson who is not a relevant person should not act or rely on thisdocument or any of its contents.Nomura Code Securities Limited ("Nomura") is acting exclusively forBiotie Therapies Corporation and no one else in connection with theplacing. It will not regard any other person (whether or not arecipient of this release) and will not be responsible to anyoneother than Biotie Therapies Corporation for providing the protectionsafforded to its clients, nor for giving advice in relation to theplacing or any transaction or arrangement referred to herein. Norepresentation or warranty, express or implied, is made by Nomura asto the accuracy, completeness or verification of the information setforth in this release.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 07.12.2009 - 08:31 Uhr
Sprache: Deutsch
News-ID 9327
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 522 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotie raises EUR 7.2 million - directed issue of new shares in
Biotie Therapies Corp. more than two"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
